| |
Good day, 360! | SPECIAL EVENT TONIGHT: Election Day triggered a 90-day window to open. A handful of stocks are destined to SOAR. Don’t wait another 4 years for this window to open! Tim Bohen’s using his breakthrough tech to identify his TOP 5 stocks set for a post-election run! Claim Your Seat HERE (*proud affiliate for StocksToTrade) | Be the best prepared trader on the Street! | | FOCUS LIST🔎 | SLXN - Up over 90% in the pre-market after reporting Q3 2024 financial results and providing business update | QSI - Up over 100% in pre after announcing its developing an acceleration platform and advance core technologies in collaboration with NVIDIA | KITT- Up over 27% in pre after announcing collaboration with SeaTrepid International to bring ToolKITT software to ROVs | | *Together with StocksToTrade | [Time-sensitive for ALL Traders - TONIGHT] | The Election just triggered an EPIC 90-day profit window! See how Tim Bohen’s powerful AI is aimed to capitalize on this situation right now. | | Register for the Big Reveal TONIGHT, 8pm EST |
|
| | HOTLIST🔥 | SLXN - Up over 90% in the pre-market after reporting Q3 2024 financial results and providing business update | Silexion Therapeutics Corp (SLXN) is a biopharmaceutical company that discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. | In the pre-market this morning, the company reported its financial results for the third quarter ended September 30, 2024, and provided an update on recent business developments. | Highlights include: | Significant advancements in clinical and preclinical programs targeting KRAS-driven cancers; company advancing pipeline with focus on challenging oncology indications. | Merger Completion : On August 15, 2024, Silexion completed its business combination with Moringa Acquisition Corp, becoming a publicly traded company on Nasdaq under the ticker "SLXN." This strategic milestone provides Silexion with greater access to capital to advance its clinical pipeline. Clinical Program Progress : The Company's first-generation candidate, LODER™, has previously demonstrated promise in clinical settings for non-resectable pancreatic cancer. As previously reported on September 24, 2024, the Phase 2 trial of LODER showed a 56% objective response rate (ORR) in patients with KRAS G12D/V mutations, with tumor resectability improving to 67% for some non-resectable cases. The trial data underscore LODER's potential to improve surgical outcomes and overall survival for patients with locally advanced pancreatic cancer (LAPC). Cash Position: Cash and cash equivalents were $2.0 million as of September 30, 2024, compared to $4.6 million as of December 31, 2023. The decrease primarily reflects operating expenses and strategic investments in advancing clinical and preclinical development as well as one-time payments associated with the SPAC merger and our public listing on NASDAQ. | Shares of SLXN traded up over 90% in the pre-market in reaction to the news. | | The $0.40 area acted as support in the per-market and will be an important level to watch. | Above it, targets to the upside are $0.46, $0.50, $0.5350, $0.5567 and then the pre-market high at $0.6110. Beyond that, $0.7210, $0.90, $1 and $1.27 come into play. | Below $0.40, targets to the downside are $0.3757, $0.30, $0.26 and then a gap fill at $0.2262. | | QSI - Up over 100% in pre after announcing its developing an acceleration platform and advance core technologies in collaboration with NVIDIA | Quantum-Si incorporated (QSI) is a life sciences company that engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments. | In the pre-market this morning, the company announced a collaboration with NVIDIA to develop its new proteomics platform, Proteus™, and advance Quantum-Si’s core technologies of amino acid binders and aminopeptidases using NVIDIA AI and accelerated computing. | This collaboration aims to significantly enhance data processing speeds to handle the increased data volume from Proteus. By leveraging NVIDIA accelerated computing and Quantum-Si’s advanced single-molecule protein sequencing and detection technologies, the collaboration aims to develop a robust data processing system. T | Shares of QSI traded up over 100% in the pre-market in reaction to the news. | | The first target for bulls is the pre-market high at $1.41. Above it, targets to the upside are $1.55, $1.75, $1.90 and then $2. | Below $1.41, targets to the downside are $1.30, $1.20, $1.10, $1, $0.87, $0.78 and then a gap fill at $0.6330. | | *Sponsored by CompareCredit | | 2 Cards Charging 0% Interest Until 2026 | Paying down your credit card balance can be tough with the majority of your payment going to interest. Avoid interest charges for up to 18 months with these cards. | Learn More |
|
| | KITT- Up over 29% in pre after announcing collaboration with SeaTrepid International to bring ToolKITT software to ROVs | Nauticus Robotics Inc. (KITT) develops ocean robots, cloud software, and services to the ocean industry. | In the after-hours yesterday, the company announced a strategic collaboration with SeaTrepid International, LLC to integrate and test its ToolKITT software on a Remotely Operated Vehicle (ROV) in SeaTrepid's fleet. | Under this collaboration, Nauticus will install a perpetual license of its ToolKITT software onto an ROV, with SeaTrepid providing access to its facilities and workforce to support pool testing during the certification process. SeaTrepid will gain a competitive edge through enhanced ROV services, while Nauticus will benefit from recurring annual software maintenance revenues post-deployment. | Shares of KITT traded up over 29% in the pre-market in reaction to the news. | | The $1.16 area acted as support in the pre-market this morning and will be an important level to watch. | Above it, targets to the upside are $1.30, $1.40, $1.50, $1.60 and then the pre-market high at $1.65. Beyond that, $1.75, $1.85, $2 and $2.20 come into play. | Below $1.16, targets to the downside are $1.10, $1, $0.95 and then a gap fill at $0.9102. | | MARKET NEWS 📰 | | | P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas! | | Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull | | DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at https://ragingbull.com/disclaimer | FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. | RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. | RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull. com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. | RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull. com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull. com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. | *Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals. | WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. |
|
|
|
